ANNOUNCEMENT

ppski

VIRTUAL MEETING

09th - 11th
April 2021
Collaboration towards the Cervical Cancer Elimination
during the COVID-19 Pandemic in Asia-Oceania
 Introduction

I am grateful to Dwiana and our Indonesian colleagues for hosting

our belated AOGIN Congress as a result of the disruption caused
by the pandemic.
We have not forgotten our Mission and WHO`s call to eliminate the
risk of cervical cancer as a public health issue within a century.
WHO hopes that 3 initiatives would be implemented by countries
around the world by 2030. Are these initiatives achievable?
Would AOGIN member countries rise to the challenge to towards
this goal?
We have been relying on screening and treatment to contain cervical dysplasia and cancers.
This process is relentless and costly. So how can we do better?
We should take a broader and longer-term perspective of managing it as an HPV-related
cancers and diseases. There lies the answer to long-term control and progressive cost-
reduction. The Covid-19 pandemic has taught the world that in dealing with a virus-related
disease, we should boost herd protection across the population, as a critical priority. We
need to focus more on Primary Prevention.
Eventually, this strategy would reduce the reliance on screening and reduced incidence of
HPV-related diseases, resulting in simplicity of disease-control and cost containment.
Together, we have to support WHO’s movement against cervical cancer. It is essential that
we work closer than before in a concerted effort to protect our community and loved ones
from preventable HPV-related diseases and cancers. Hence, our Theme for this Congress :
Collaboration towards the Cervical Cancer Elimination.
Thank you and I hope everyone enjoys this virtual Congress.
Yours sincerely,
E.H Tay

01
 Introduction

Dear Colleagues and Friends,

On behalf of the Local Organizing Committee of The Asia-

Oceania Research Organisation in Genital Infection and
Neoplasia (AOGIN), we are delighted to invite you to participate
in the Virtual AOGIN meeting from April 9th-11th April 2021.
Cervical cancer is 2nd most common female cancer in
Indonesia. There are about 93.15 millions reproductive women
ages 15 and above who are at risk to cervical cancer. There has been many initiatives and
programs that focus on early diagnosis and prevention of cervical cancer in Indonesia to
reach our goals in the elimination of cervical cancer.
Our focus on this meeting is “Collaboration towards the elimination of Cervical Cancer
in Asia-Oceania in Pandemic Era.” There will be lectures from local and invited speakers,
workshops, and poster session, AOGIN board and regional meetings. Together we will plan
reliable and strong plans on Cervical cancer eliminations in the Asia-Pacific Regions.
I would like to thank the committee and everyone who contributes in this virtual event.
Hopefully, we can achieve the goals of this conferences.

Yours sincerely,
Dwiana Ocviyanti

Important Date :

No Activities Time
1 Workshop 9 April 2021
2 Abstract Submission deadline 27 March 2021
3 AOGIN Meeting 10 - 11 April 2021

02
About AOGIN

www.aogin.com
AOGIN Board Member

Prof Eng-Hseon Tay President
Prof Wisit Supakarapongkul President Elect
Prof Efren Domingo Immediate Past President
Prof Young-Tak Kim Vice President & Education
Committee Chair
Karen Chan Secretary General
Prof Janice Chin Treasurer
Prof Fang-Hui Zhao Research Committee Chair
Neerja Bhatla Advisor
Prof Karen Canfell National Representative And Website
Prof Suzanne Garland Advisor
Prof Jong Sup Park Advisor
Prof You Lin Qiao Advisor
Jeffery Tan Advisor
Hextan Ngan Advisor
Prof Dwiana Ocviyanti National Representative
Prof Annie Cheung Advisor
Prof Ashrafunnessa National Representative
Prof Ryo Konno National Representative
Prof Yin Ling Woo National Representative
Prof Jae-Weon Kim Membership
Prof Tang-Yuan Chu Liaison Officer

Local Committee
Advisor Endy Moegni
Andrijono
Chairman Dwiana Ocviyanti
Secretary Fitriadi Kusuma
Treasurer Junita Indarti
Scientific Commitee Hariyono Winarto
Andi Dharma Putra
Gatot Purwoto
Member Nation/District
Australia Japan Malaysia Sri Lanka
Bangladesh Indonesia Myanmar Taiwan
Brunei Kampuchea Nepal Thailand
China Korea New Zealand Vietnam
Hong Kong Laos Philippines
India Macau Singapore

03
 International Speakers

1. AOGIN, Collaboration towards the elimination of

Cervical Cancer in Asia-Oceanian - Prof. Eng Hseon Tay
• One of the founding members and honorary treasurer
of AOGIN.
• Currently the President of AOGIN and Medical director
of Thomson Women Cancer Centre, Singapore.

2. Update on Cervical Tumors in Fifth Edition WHO Classification of Gynaecology Tumours -

Annie Nga-Yin Cheung
• Laurence L T Hou Professorship in Anatomical
Molecular Pathology, The University of Hong Kong
(HKU)
• Clicical Professor, HKU
• Chief of Service (Pathology), HKU-Shenzen Hospital
• Standing Member, Editorial Board, WHO
Classification of Tumours 5th Ed
• Director, International Collaboration of Cancer
Reporting (ICCR) board director
• Advisor to AOGIN

04
 International Speakers

3. Progress in Implementing the WHO Strategy for Cervical Cancer Elimination in India – Prof. Neerja
Bhatla
• Professor in the Department of Obstetrics & Gynecology at the All India Institute of
Medical Sciences, New Delhi, India,
• Special interest in gynecologic oncology and preventive
oncology
• Chairperson of the FIGO Committee for Gynecologic
Oncology (2015-2018)
• Had undertaken numerous research projects in India
on cervical cancer prevention, including screening in
low resource situations, human papillomavirus (HPV)
epidemiology, trials on affordable HPV tests and -HPV
vaccine, and new strategies for the elimination of
cervical cancer
4. Effectiveness of High-risk HPV testing for Cervical Cancer Screening in China : A
Multicenter, Open-Label, RCT - Prof. Youlin Qiao
•
• Professor and Director for Department of Cancer
Epidemiology, National Cancer Center, Cancer Hospital,
Chinese Academy of Medical Sciences and Peking Union
Medical College Beijing, China.
• Director of International Collaboration Department,
Cancer Foundation of China, and Deputy Director of the
MOH National Expert Committee for Cancer Screening
and Prevention in China.
• WHO Director-General’s Cancer Control Advisory
Committee and WHO’s Cancer Technical Advisory Groups

05
 International Speakers

5. Two year experience with HPV screening from Melbourne, Australia – Prof. Karen Canfell
• Director of the Cancer Research Division at Cancer Council NSW and Adjunct Professor
at Sydney Medical School, University of Sydney.
• D.Phil. (PhD equivalent) in Epidemiology from the
University of Oxford

6. A Worldwide Analysis of Cervical Cancer Incidence and

Mortality Rate in 2018 - Prof. Marc Arbyn
• Diplomas of MD, MSc and Dr in tropical medicine
• Editor of the European Guidelines for Cervical
Cancer Screening and associated Supplements on
HPVscreening

06
 International Speakers

7. Current Guideline in the Management for Early Stage of

Cervical Cancer - Karen Chan
• Clinical Associate Professor, Li Ka Shing Faculty of
Medicine
• Had numerous research in gynecology oncology
• Senior vice-president of HKCOG
• Secretary General of AOGIN

8. The Role of Colposcopy in the Management of Positive Cervical Cancer Screening in

Referral Hospitals - Prof. Hextan Ngan
• Head of Department of Obstetrics & Gynaecology,
the University of Hong
• Head of the gynaecological oncology team and
laboratory of the University of Hong Kong
• Chair of Specialty (“COS”) for Obstetrics &
Gynaecology, Gleneagles Hong Kong Hospital
Limited.
• ADVISOR of AOGIN

07
 International Speakers

9. Strategic Approach to Increase the Coverage of Cervical

Cancer Screening - Dwiana Ocviyanti
• Vice Dean Faculty of Medicine Universitas Indonesia
• Head of Indonesia Society Of Cervical Patholggy and
Colposcopy

10. Advances in Histopathology of CIN - Hartono Tjahjadi

• Anatomical pathologist who specializes in cervical cells

08
 International Speakers

11. Hormone Receptor in Cervical Cancer Stroma: Favorable prognostic Markers Conferring Less
Hemaogenous Metastasis - Prof Chu Tang-Yuan
• Professor and Coordinator, Program of Clinical Medical
Medicine, Institute of Medical Sciences. Tzu Chi University,
Hualien. R.O.C.
• Professor, Department of Obstetrics and Gynecology,
National Defense Medical Center, R.O.C.
• Professor and Dean, Graduate Institute of Medical
Sciences, National Defense Medical Center, R.O.C.
• Chief, Department of Research, Buddhist Tzu Chi Medical
Center, Hualien, R.O.C.

12. DNA Methylation for the triage ov HPV infection and diagnosis of cervical cancer - Prof.
Hung-Cheng Lai
• Vice Superintendent, Taipei Medical University
Shuang Ho Hospital
• 2017.08- Professor, International Master/Ph.D.
Program in Medicine, College of Medicine, Taipei
Medical University
• 2017.08- Professor, International Ph.D. Program
for Cell Therapy and Regeneration Medicine,
Taipei Medical University

09
 Topics - Speakers

April 10th, 2021

TOPICS - SPEAKERS
Welcome remarks
Keynote 1 : Theme: AOGIN, collaboration towards the elimination of Cervical Cancer in Asia-Oceanean in the
Prolong Pandemic of COVID-19 - President AOGIN - Eng Hseon Tay
Keynote 2 : Theme: The Strategy of Cervical Cancer Elimination in Indonesia (Ministry of Health of Indonesia)
Keynote 3 : Theme: WHO Initiative towards the Elimination of Cervical Cancer (WHO)
Session 1
A Worldwide Analysis of Cervical Cancer Incidence and Mortality Rate in 2018 - Marc Arbyn
Research Progress on Worldwide Primary Preventive Program of Cervical Cancer - Neerja Bhatla
Human Papilloma Virus: Recent Development and Global Perceptive - Head of IFCPC (TBC)
Session 2
Screening Cervical Cancer in Primary Health Care
Moderator : Suwiyoga / Co-Moderator : Seno Adjie
Strategic Approach to Increase the Coverage of Cervical Cancer Screening - Dwiana Ocviyanti
The feasibility and performance of Thermal Ablation in China: a population-based screening study - Fanghui
Zhao
Diagnosis of Recent Management of Positive Pre-Cancer Lesion
Moderator : Annie Nga-Yin Cheung / Co-Moderator : Budiningsih
Update in Cervical Tumors in Fifth Edition WHO Classification of Gyanecological Tumors - Annie Nga-Yin
Cheung
Pitfalls of Pap smear Results in Cervical Precancerous Lesion - Junita Indarti
Advances in Histopathology of CIN - Hartono Tjahjadi
Discussion
Recent Management of Cervical Cancer in Referral Hospital
Moderator : Neerja Bathla / Ko-Moderator : Andi Darma Putra
Screening of Cervical Cancer in Low Resource Facilities - Laila Nuranna
Effectiveness of High-risk HPV testing for Cervical Cancer Screening in China : A Multicenter, Open-Label, RCT
- Youlin Qiao
Progress in Implementing the WHO Strategy for Cervical Cancer Elimination in India - Neerja Bathla
Discussion
Hormone Receptor in Cervical Cancer Stroma: Favorable prognostic Markers Conferring Less Hemaogenous
Metastasis - TY Chu

10
 Topics - Speakers

April 11th, 2021

TOPICS - SPEAKERS
Session 3
Moderator : Hariyono / Ko-Moderator : Ediwibowo
Preventing HPV related diseases & cancers in Males - Yin Ling Woo
Preventing HPV related diseases & cancers in Adults - Suresh Kumarasamy
Real World Effectiveness - Yin Ling Woo
Update on Clinical development for HPV vaccines - Andrijono
Session 4
HPV Vaccine (Clinical Science)
Moderator : Karen Chan / Ko-Moderator : Iris Rengganis
Update on HPV Vaccine for Children - Rini Sekartini
Condylomata acuminata and Quadruvalent HPV Vaccine - Wresti Indriatmi
DNA Methylation for the triage ov HPV infection and diagnosis of cervical cancer - Hung-Cheng Lai

2 year experience with HPV screening from Melbourne, Australia - Karen Canfell
Screening in Referral Hospital
Moderator : Hextan Ngan / Ko-Moderator : IPG Kayika
Current Guideline on the Management for Early Stage of Cervical Cancer Tomours - Karen Chan
The Role of Colposcopy in the Management of Positive Cervical Cancer Screening in Referral
Hospitals - Hextan Ngan
The Treatment of Pre - Cancer Lesion in Low Resource Setting during Pandemic Era - Fitriyadi
Kusuma
Updates on Cervical Cancer Staging
Moderator : Sarah Dina / Ko-Moderator : Kartiwa
Revised FIGO staging of cervical cancer - Gatot Purwoto
Recent Guideline in the Management for Advance Stage of Cervical Cancer - Yudi Mulyana
Updates on Vulval and Vaginal Tumours in the 5th Edition WHO Classification of Tumours - What is
new? - Richard Wong

11
 Registration

Registration Fees

DESCRIPTION TIME INTERNATIONAL LOCAL

9 - 11 April
PHYSICIAN (Obgyn Specialist) with Workshop USD 75
2021
IDR 1.000.000
PHYSICIAN (Obgyn Specialist in Low Income 9 -11 April
USD 60
Economies*) with Workshop 2021
PHYSICIAN (Other Spesialist General 10 - 11 April
USD 50
Practitioner) 2021
IDR 700.000
PHYSICIAN (General Practitioner in Low Income 10 - 11 April
USD 50
Economies*) 2021
10 - 11 April
MIDWIVE / NURSE USD 40 IDR 500.000
2021
* Afghanistan, Guinea-Bissau, Sierra Leone, Burkina Faso, Haiti, Somalia, Burundi, Korea, Dem. People’s Rep,
South Sudan, Central African Republic, Liberia, Sudan, Chad, Madagascar, Syrian, Arab, Republic Congo, Dem. Rep,
Malawi, Tajikistan, Eritrea, Mali, Togo, Ethiopia , Mozambique, Uganda, Gambia, Niger, Yemen, Rep. Guinea, Rwanda

Registration Terms and Conditions

1. International participants can register online from event website: www.aogin2021.com and pay
the registration fee by visa or mastercard.

2. Local participants can register online from event website: www.aogin2021.com and pay the
registration fee by transfer to virtual account or pay transfer to:

Bank Name : Mandiri Bank

Account Name : HOGSI – AOGIN 2020

Account Number : 122-00-1031324-8

3. Registration can only be processed with full payment.

4. Email confirmation will be sent upon receipt of your registration form and full payment. If you are
not able to receive the confirmation within two weeks, please contact the Secretariat.

5. Transfer of registration is allowed provided the replacement is from the same organization and
upon receipt of a written request from the person to be replaced. Please note that substitution is
permitted on the basis that written notice is received on/before March 9, 2021.

12
 Poster Session

6. The date of payment is decisive for the registration fee. Even if the registration form is received
before the early bird or regular deadline, it will not be considered as early or regular registration if
the payment has not been received before the deadlines.

7. Please note that all bank charges are to be borne by the delegate

8. The program is subject to change without prior notice. In the unlikely event of cancellation of the
meeting, the only liability of the Organizer is to refund the registration fee.
The AOGIN 2021 Organizing Committee is offering an online platform for accepted
authors to upload virtual poster presentations. In order to be eligible, the following steps
should already be completed :
1. Your abstract must be submitted online not later than 00:00 (GMT +7) 27 March 2021
into [email protected]
2. Authors can submit more than one paper.
3. Papers must not have been published elsewhere.
4. All papers will be presented by poster presentation
5. Abstracts must be submitted in English
6. Material presented in abstracts must be concise and coherent, with the focus of the
abstract stated clearly.
7. Abbreviations should be spelled out, in parenthesis, in its first use in the abstract
8. The authors must make explicit what they intend to present.
9. Relevant contextual information must be given.
10. Upon submission, authors will receive a confirmation by email. Please ensure that your
email address is correct at the time of submission. It is therefore incumbent upon the
author to ensure that the spelling, grammar, and syntax are of an academic publishing
standard.
11. The Organizing Committee reserves the right to select and assign the abstracts
relevant. All presenting authors of the abstracts are required to register and pay for the
registration fee by the deadline in order for the abstract to be presented.
12. The Organizing Committee will choose 3 Best Poster at the end of the meeting.

13
 Poster Session

Virtual Poster Session | Create The Poster

• Poster is created in PDF Format and using Powerpoint program
• 16:9 aspect ratio landscape orientation
• Poster should be written ONLY in English language
• Use easy-to-read fonts such as Arial or Times New Roman
• Submit a five-minute or less video recording that can poster visitors will be able to see. 
We suggest that you summarize the following:
1. study’s objective and significance
2. methods used
3. results obtained
4. conclusions and implications
• Presenter will be required to upload the Poster & pre-recorded presentation by March 30
2021 (deadline)
• All recorded presentations required to be submitted as a .MP4 file, along with a copy of
your poster.
• We require that you record your presentation using Zoom format.
• Please send your video file and PDF Poster to: [email protected]

Abstract Title
Author + Institutes

VI
I III
Result and
Objectives Materials + Methods
Conclusion

II IV V VII

14
 Poster Session

Virtual Poster Session | Template

Virtual Poster Session | Overview at Website

Topics for Posters

• Precancer and Cancer Cervix
• Vaginal and Vulvar Pre Cancer
• Lower Genital Tract Infection
• Human Papilloma Virus
• HPV Vaccines
• Cervical Cancer Screening and HPV Detection
• Colposcopy Training

15
 Abstract Submission

Abstract Submission Guidelines

• All selected abstracts will be published in the proceeding book
• Abstracts have not been published elsewhere
• Reference must be included
• Abstract title: The title has a maximum word limit of 12 words and must be brief, informative
and concise
• Maximum number of words: The abstract text should have a minimum of 800 words and
maximum of 1000 words only
• If you wish to include key words and references; they must be included in the body of your text
and within the 800 word count
• For original articles, the format is title, authors’ names, affiliations, correspondence address,
abstracts (in English), introduction, methods, results, discussion, conclusion and references.
• For case reports, the format is title, authors’ names, affiliations, correspondence address,
abstracts (in English), introduction, methods, results, discussion, conclusion and references
• For systematic reviews, the format is title, authors’ names, affiliations, correspondence
address, abstracts (in English), introduction, review, conclusion and references.
• Special symbols and formatting should be used sparingly
• Tables and images cannot be included in your abstract
• Authors: Please enter your name and ALL your colleagues’ authors in the order and the form
you wish them to appear in the final programme in the order in which you wish them to appear
in the printed text. Names omitted here will NOT be printed in the author index or the final
programme. Please note that only named authors are permitted to present
• Content: Each abstract must contain sufficient details for evaluation. Make the abstract as
informative as possible. Clearly indicate the aims and conclusions supported by data. Results
stated in the abstracts must be complete (though concise) and final.
• Organize the body of the abstract as follows:
(a) Background/Objectives;
(b) Methods
(c) Results
(d) Discussion
(e) Conclusions
(f) Keyword
16
Poster Session

ORIGINAL ARTICLE ABSTRACT

Page layout: Size A4; Orientation Portrait; Margin TRLB 3 cm; Line space 1.5; Paragraph after &
before 0pt; Word limit 250 words

Full Title (TNR 14 bold; Capitalize each word; Specific, descriptive, concise, and comprehensible
to readers outside the field; length 250 characters)
Author A1*, Author B1, Author C2, Author D2, and so on
(Complete full name, TNR 12 unbold, separate with comma, use superscript for numbering
affiliations, add * icon in the name of corresponding author)
1Affiliations 1, 2Affiliations 2, and so on
(TNR 12 unbold; 1Division, Department, Faculty, University, City, Country; 2and so on)
Email of Corresponding author (TNR 11 unbold; only one active email)
Background/Objective
TNR 12; alignment justify; Explain the study background and objectives.
Methods
TNR 12; alignment justify; Explain how the study was done, including any model organisms
used, without methodological detail.
Results
TNR 12; alignment justify; Summarize the most important results and their significance.
Discussion
TNR 12; alignment justify; General interpretation of the results.
Conclusions
TNR 12; alignment justify; State the principal conclusion.
Keywords
TNR 12; 3–5 relevant keywords; use established keywords and terminology from the literature
and databases, such as MeSH and PACS.

17
 Absrtarct Submission

Conflicts of Interest Statement

Abstract title:

_____________________________________________________________________________________
The authors whose names are listed immediately below certify that they have NO affiliations with or
involvement in any organization or entity with any financial interest (such as honoraria; educational
grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or
other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest
(such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter
or materials discussed. Also the author states that this abstract has never been published before

Author names:

This statement is signed by all the authors to indicate agreement that the above
information is true and correct

Author’s name (typed) Author’s signature Date

_______________________ ____________________ _______________

18
 VIRTUAL MEETING

Committee Secretariat : Jl. Kimia No. 5, Jakarta Pusat, Indonesia

Email for scientific : [email protected]
Email for registration : [email protected]
Phone : +62-21-3928721
Whatsapp : +6281282868612
www.aogin2021.com